Alkem to accelerate its non-US business as part of long-term growth plans: CEO

The company’s total revenue from operations stood at ₹3,371 crore, up 11.2 per cent from the same period last year
| Photo Credit:
Artsanova

Drugmaker Alkem is looking to accelerate its non-US business as part of long-term growth plans, said the company management. It also announced the setting up of a subsidiary in Saudi Arabia.

“We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high-potential non-US markets and capturing new opportunities that align with our long-term growth ambitions,” said Alkem Chief Executive Vikas Gupta after the company announced its financial performance for the first quarter ended June 30.

Revenue rises

The company’s total revenue from operations stood at ₹3,371 crore, up 11.2 per cent from the same period last year. Its net profit (after Minority Interest) stood at ₹664 crore, up 21.8 percent, compared to the same period last. Alkem’s US business accounts for about 21 per cent of its revenues in the quarter under review.

US tariffs

The statement comes against the backdrop of US tariffs expected on the pharma segment. However, company insiders indicated the plans to build on its non-US plans were not triggered by the ongoing tariff-linked uncertainty.

In a separate announcement, Alkem said it was incorporating a subsidiary in Saudi Arabia, in which it would hold 51 per cent, the rest being held by the Saudi Partner, the company said. The yet-to-be incorporated subsidiary will operate in the pharma and nutraceuticals segment, it said, without divulging financials.

“The proposed investment in the subsidiary is a strategic investment undertaken by the company with the objective of expanding the company’s business and market reach to the Kingdom of Saudi Arabia,” it said, adding that it would be established within a year of the execution of the Shareholders’ Agreement.

Alkem’s India sales for the quarter under review stood at were ₹2,265 crore, up 12 per cent over the same period last year. Domestic sales contributed about 68 per cent to total sales in Q1 FY26. Alkem’s US sales were ₹698 crore for the period under review, up 8.8 per cent over the same period last year. Its international sales stood at ₹1,053 crore, up 8.9 per cent over last year. Alkem’s non-US sales stood at ₹355 crore, up 9 per cent over the same period last year. Its non-US business sales contributed 10.7 per cent of total sales in Q1 FY26.

Published on August 12, 2025